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spread use of the EQ-5D a number of country-specific scoring systems have been
developed. The objective of this study was to identify and compare all existing
EQ-5D valuation studies and country-specific scoring systems.METHODS:An elec-
tronic search of MEDLINE, EMBASE, NHS EED, HEED and a search through the past
proceedings of the Euroqol group up to September of 2010 was conducted to iden-
tify all EQ-5D preference elicitation studies. The review included a summary and
comparison of study design, model estimation, study demographics and scoring
function. RESULTS: After screening 2940 citations identified from the literature
search, 33 elicitation studies that contained a unique scoring systemwere included
for final review. The key areas of divergence between the studies include: differ-
ences in methodology used to directly value health (i.e. SG, TTO, etc.), the number
of health states that were directly valued, the transformation of the directly valued
health states, the statistical methods used to derive the scoring system, and the
model variables included in the scoring system. CONCLUSIONS: Differences in
methods do exist between population studies. Knowing the extent, at which the
identified methodological differences can explain the variation, will help deter-
mine whether a global preference for health exists.
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OBJECTIVES: TheMVH protocol uses a valuation subset of 43 EQ-5D states. Smaller
valuation subsets would allow smaller samples if all respondents can value one set
of states. This study tests the performance of valuation subsets based on orthogo-
nal experiment designs. VAS values obtained for EQ-5D states are affected by the
identity of adjacent states in the elicitation. This study also tests a VAS protocol
developed to minimize such effects. METHODS: 230 respondents were each ran-
domly assigned to one of two orthogonal EQ-5D valuation subsets. EQ-5D states
were printed on 9cm x 4cm cards with rhomboid edges. Respondents first ranked a
shuffled deck of 23 cards. A 1 meter VAS was then placed next to the ranked cards.
Respondents transferred the cards on to the VASwith the rhomboid edges pointing
to the respective values. They could see all of the cards in place at the same time.
Ties were permitted and respondents were free to change the order of states in
moving the cards from the ranked order to the VAS. RESULTS: OLS regression of
VAS Scores produced internally valid models for both valuation subsets with r2 of
0.54 and 0.56. Within sample comparisons of model versus observed VAS values
produced residuals of MAD 3% with individual values crossing 6 VAS points in
only 2 cases. Rank correlation coefficients between model and observed states
0.996. Comparisons across the two subsets/subgroups produced residuals of
MAD4 VAS points and rank correlation coefficients of 0.98 and 0.96.
CONCLUSIONS: This study suggests that orthogonal experiment designs may be
suitable as the basis for the construction of EQ-5D valuation subsets, which can
allow for smaller respondent samples. The statistical properties of the models
arising in this study suggest that some concerns with VAS methods for EQ-5D
elicitations may be reduced using this protocol.
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OBJECTIVES: Patient-reported outcome (PRO), health-related quality of life
(HRQOL), and related instruments are increasingly used in outcomes research. In
developing and evaluating PRO, HRQOL, and related instruments, measurement
validity is a fundamental consideration. With an eye toward investigating the
methodology of validity and uses of validation, we systematically reviewed the
reporting of validation practice in papers published in Value in Health, the Inter-
national Society for Pharmacoeconomics and Outcomes Research (ISPOR) official
journal. METHODS: A systematic search using the journal official website was
conducted inDecember 2010 – including papers since its inception (January 1998) to
December 2010. Two searches were independently conducted by two of the au-
thors. Keywords used in the search included “development OR measurement OR
psychometric OR psychometrics OR valid OR validation OR validity.” We searched
both the titles (126 citations) and abstracts (347 citations). Papers reporting empir-
ical results on validitywere included. Econometric, opinion, and conference papers
were excluded. A coding sheet was developed and each article was double-coded
independently by at least two of the authors. RESULTS: Ninety-three articles met
the inclusion criteria. The percentage of reports of the broad categories of validity
evidencewere: construct (39.8%), discriminant (28.0%), convergent (26.9%), content
(17.2%), concurrent (14.0%), predictive (5.4%), response processes (4.3%), and con-
sequences (1.1%). A paper may report more than one type of validity evidence. In
addition, 95.7% of the papers referred to the validity of the instrument, rather than
the modern view of validity of the inferences from the scores. CONCLUSIONS:
Findings reveal that validity information is not routinely presented from amodern
validity perspective; that is, consider a unitary view of validity, cite recent theoret-
ical papers in validity theory, or distinguish between validity (as a property) and
validation (as a process/method). Some sources of validity evidence (e.g., conse-
quences and response processes) are essentially ignored.
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OBJECTIVES: To establish the concept that it is best practice to provide training to
patients on how to utilize electronic patient reported outcome (ePRO) systems
before patients begins study participation. METHODS: Methods on how to ap-
proach training patients on ePRO systemswill be presented and recommendations
will be discussed. To provide supporting evidence and information on best prac-
tices used in ePRO, a literature review was conducted to identify articles reporting
on studies that utilized ePRO. Of that, articles were identified that reported provid-
ing training to their patients on the ePRO portion of the study prior to participation.
Rates of ePRO compliance are examined and approaches to training patients are
identified within the articles. RESULTS: Out of the 115 articles identified using
ePRO, 55 (47.8%) reported providing ePRO training to their patients. ePRO compli-
ance rates of studies with patient training were overall high (Mean85.08, Stan-
dard Deviation9.83). Training methods reported included: training session, pro-
viding demonstration, giving instruction, question/answer session, subject
hands-on practice, written instructions/reference material, and testing of mastery
of ePRO tool. Duration of training reported ranged from 1 minute to 4 hours.
CONCLUSIONS: Best practice for training patients is to have a combination of the
methods reported above. Having available a dummy system for training is most
important so that demonstration can be provided, patients can practice using the
system and patients can see exactly what they need to do during their actual study
participation. Questions can be addressed and patients can begin the study with a
clearer understanding of what to do during participation. Training patients allows
for higher comfort levels in use of system, thus alleviating frustration and burden.
Furthermore, when patients are trained, they require less support throughout the
duration of the study. Overall, training patients will lead to better experiences for
patient participation.
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OBJECTIVES:Assessments composed of patient-reported outcome (PRO)measures
can be used in health care settings as screeners for various conditions. The objec-
tive of developing and using a PRO screening measure may be to quickly identify
patients who are likely to benefit from a formal diagnostic evaluation. Alterna-
tively, the development objective may be to avoid unnecessary diagnostic proce-
dures, particularly when these are time or resource-intensive or invasive in nature.
The PRO screener may also be administered to simply rule out the existence of a
particular condition. The evaluation of a PRO screening assessment ideally occurs
through analyses using a “gold standard” diagnosis of the condition of interest.
METHODS: A number of existing statistical and psychometric methods may be
used in such an evaluation, including sensitivity and specificity, positive and neg-
ative predictive value, kappa, accuracy, odds ratio, and likelihood ratio. RESULTS:
The evaluation method selected depends on the objective of the screener itself. If
the formal diagnostic procedures are particularly invasive or time- or resource-
intensive, then screeners should minimize false positives; in contrast, diseases
with exceptional riskswhen left undiagnosed call for screeners thatminimize false
negatives. In this research, we explore these methods using data from a study
comparing various fibromyalgia screening instruments with the currently ac-
cepted gold standard diagnosis for fibromyalgia, namely the American College of
Rheumatology 1990 diagnostic criteria (Wolfe et al., 1990). CONCLUSIONS: Using
the example application, we illustrate the pros and cons of a battery of statistical
methods and how they can be used to select the “best” candidate screener.
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OBJECTIVES: In its guidance on the use of PRO measures, the FDA recommends
that sponsors provide evidence that the content validity and other measurement
properties are adequately similar across all versions used in a clinical trial. One
way to ensure the comparability of content is to ensure that all translations reflect
the original item intent. As this presupposes the existence of a formal description
of each item concept, it is the objective of this study to investigate if this was the
case prior to the guidance publication and to make recommendations on the basis
of our findings.METHODS: The research is based on the review of PRO translations
performed between 1995 and 2009. RESULTS: A total of 640 questionnaires (27
generic and 613 disease- or condition-specific) were translated. All were developed
before the publication of the FDA’s PRO guidance. None had a formal written doc-
ument listing a definition of each item concept and possible translation alterna-
tives available before launching the translations. In all cases, the item-by-item
concept list and the list of translation alternatives were developed in collaboration
with the developers of the original questionnaires during the translation process.
In some cases (multiple projects involving different languages for the same ques-
tionnaire), the development of the concept list was a dynamic process fed by ques-
tions raised at each new translation [e.g. Quality of Life in Inflammatory Bowel
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Disease Questionnaire (IBDQ)]. Over the years a standardized document was de-
veloped to help the authors to clarify the concepts and intent of each item of their
questionnaire(s). This document and examples will be presented. CONCLUSIONS:
This review demonstrates the lack of a formal, written concept lists for PRO ques-
tionnaires developed before the publication of the FDA guidance and the need to
develop standardized documents. Involvement of the developer(s) is crucial at this
step.
Research on Methods – Statistical Methods
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OBJECTIVES: Typically, mean costs and mean measures of effectiveness are used
in the estimation of the incremental cost effectiveness ratio (ICER). Cost and effec-
tiveness distributions, however, are often skewed. The goal of this work is to use a
nonparametric generalization of location to obtain a location region in the cost
effectiveness plane. The region accounts for uncertainty and all points in the re-
gion are appropriate estimates of the ICER that account for skewness in the mar-
ginal distributions.METHODS: First, analogous toMann-Whitney, all pairwise cost
and effectiveness treatment differences are computed. Using univariate methods,
an estimate of a location rectangle is obtained as the Cartesian product ofmarginal
location intervals, intervals that account for skewness. By considering the inter-
section of such rectangles over all orthogonal transformations, a closed convex
region is obtained. This method will then be applied to simulated bivariate cost
effectiveness data using both symmetric and skewed distributions. Kolmogorov-
Smirnov provides simultaneous confidence bands for each univariate rectangle.
Any point of this region is an estimate of the ICER; all such points satisfy basic
axioms of bivariate location. This approach will also be used to construct a gener-
alization of the cost effectiveness acceptability curve with uncertainty incorpo-
rated. A test for marginal skewness can precede the construction of the location
region. RESULTS: By comparing the location region with the usual bootstrap esti-
mates for the ICER, it was found that the location region approach produced con-
fidence intervals that were considerably larger for both skewed and symmetric
distributions of costs and effectiveness. CONCLUSIONS: This work provides esti-
mates of the ICER that appropriately accounting for skewness. In such cases, the
mean is not the best measure of location. In spite of the used of the nonparametric
bootstrap to obtain confidence intervals, skewness introduces an extra element of
variability that should be accounted for.
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OBJECTIVES: To show how the discrete modelling of continuously varying dose-
response relationships in cost-effective analysis (CEA) influences incremental
cost-effectiveness ratios (ICERs), cost-effectiveness acceptability curves (CEACs)
and the expected value of perfect information (EVPI). In particular, to show that
each of these metrics is contingent on the discrete comparisons chosen within a
CEA.METHODS: The cost-effectiveness of a hypothetical intervention with a con-
tinuous dose-response relationship is simulated. The cost-effectiveness of a small
number of possible dose levels is simulated first. The analysis is then repeated a
number of times, progressively increasing the number of possible doses and result-
ing combinations of costs and effects. For each run of the analysis ICERs are calcu-
lated for each dose level, a probabilistic sensitivity analysis is simulated, and
CEACs and the EVPI are plotted. RESULTS: As the number of potential cost and
effect combinations increases, the ICERs for each dose level increase, the CEACs fall
towards zero and the EVPI both rises and changes from having sharp inflection
points to being a smooth, downward-sloping curve. CONCLUSIONS: Many inter-
ventions demonstrate dose-response relationships, most of which are in principle
continuous, even if doses are typically varied discretely. The continuously increas-
ing intensity of interventionsmeans the number of possible alternatives is infinite.
The general conclusion from the analysis is that each of themetrics presented here
are contingent on the discrete comparisons chosenwithin the analysis. The signif-
icance of this finding for CEACs depends on their interpretation,which varies in the
literature. The significance for EVPI is that while it has previously been recognised
that excluding relevant comparators can reduce the EVPI, including all theoreti-
cally relevant alternatives may be impossible. Further work may be required to
understand this constraint on measuring the upper bound of the value of further
research.
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OBJECTIVES: To develop new schemes which can make the cost-effectiveness ac-
ceptability curve (CEAC) augmented to be more informative regarding the types of
acceptance and statistical inference.METHODS:Theoretical approaches have been
undertaken to address two questions: how the area under the curve (AUC) can be
zoned by the types of acceptance, and how the accepted dataset of incremental
cost-effectiveness ratios (ICERs), which are generated by computer runs, can be
statistically associated with a standard threshold of ICER. RESULTS: The AUC of a
typical sigmoid-shaped CEAC was divided into three zones, each of which repre-
sents the proportion, pi  ni / n(0), where ni is the number of plots on the cost-
effectiveness plain belonging to the quadrant i (i1:South-East, 2:North-East and
3:South-West), and n(0) is the total number of plots (i.e., n(0)n1n2n3) ac-
cepted for the threshold, 0, of ICER. A solution for the second question was “a new
CEAC of themean (MCEAC)”, which can be constructed by plotting a pair of m0 and
p0 instead of a pair of 0 and p0, where 0: the threshold of ICER for acceptance, p0:
the probability of acceptance for the threshold 0, and m0: the mean ICER of all the
plots accepted for the threshold 0. Also, statistical validity of the MCEAC was
inferred by the confidence interval of the mean m0 using t-test. Furthermore, the
series of confidence intervals defined for one threshold 0 corresponding to differ-
ent size of computer runs were summarized as a diagram for showing the progres-
sion of the confidence intervals, which looks similar to the forest plot in meta-
analysis. All those schemes were graphically illustrated based on examples.
CONCLUSIONS: Visualizing the component types of acceptance in the AUC, draw-
ing theMCEAC, and the progression diagramof confidence intervalswill provide us
with more useful information on cost-effectiveness decisions.
Research on Methods – Study Design
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OBJECTIVES:The objectivewas to summarize the impact of pharmacists’ interven-
tions on patient outcomes as reported in studies utilizing a randomized controlled
trial (RCT) design. METHODS: A comprehensive literature search was conducted
utilizing PubMed and International Pharmaceutical Abstracts for the years 1979-
2009. Studies were included if they evaluated pharmacist-provided interventions,
utilized RCT designs with control groups, andwere conducted in the United States.
Studies were summarized by 1) publication year; 2) study setting; 3) disease/health
condition; and 4) type of intervention provided and whether performed by a phar-
macist alone or a pharmacist with other health care professionals, 5) primary out-
come variables and 6) study findings. Patient outcome results were categorized as
‘positive’, if they found a statistically significant improvement in the patient out-
comes when compared to the control group, or ‘no difference’ if no significant
difference was found. RESULTS: Of the 552 citations reviewed, 100 studies met the
inclusion criteria. The numbers of pharmacists’ intervention studies conducted
using RCT designs increased from 1979 to 2009, with 64% conducted after 2000. The
majority of the studies were conducted in clinic setting (65%) followed by commu-
nity pharmacies (19%), hospitals (12%), home-care (2%), andmultiple settings (2%).
Chronic conditions were studied in 56% of the studies. Studies of interventions
delivered by pharmacists alone comprised 64%, while 36% involved pharmacists
workingwith other health care providers. Overall, ’positive’ patient outcomeswere
demonstrated in 73% of the studies. When interventions were delivered by phar-
macists working with other health care providers, however, 97.2% had positive
outcomes. CONCLUSIONS: ‘Positive’ patient outcomes were demonstrated in the
majority of the studies, supporting increased pharmacists’ roles in the health care
system to improve patient outcomes. When working alongside other health care
providers, the positive impact was most likely.
Research on Methods – Conceptual Papers
PRM40
ISSUES CONCERNING THE TRANSLATION OF THE WORD ‘HASSLED’ IN THE
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OBJECTIVES: The word ‘hassle’ is commonly used in PRO measures including the
Morisky Medication Adherence Scale (MMAS-8). The translation of the word ‘has-
sle’ is used as an example of how creation of a concept elaboration and a full
translation and linguistic validation process can result in a translation that is con-
ceptually equivalent to the source text and to aid in the future translation of am-
biguouswords.METHODS:TheMMAS-8was translated into 29 languages using the
standard methodology of two forward translations, reconciliation, two back trans-
lations, back-translation review, developer review and proofreading. Examples of
translation issues of the word ‘hassled’ in the following statement were assessed:
Do you ever feel hassled about sticking to your anti-rejection treatment plan?
RESULTS: A ‘hassle’ is defined in the Oxford English Dictionary as an ‘irritating
inconvenience’. In the above question, this word encompasses several concepts –
bothered, troubled, disturbed – which were provided to translators in a concept
elaboration document. The translation process resulted in the following: The initial
French translation was back-translated as bothered/annoyed. Alternatives back-
translating as ‘preoccupied’ and ‘inconvenient’ were suggested but rejected. The
developer piloted the final suggestion, debordé (overwhelmed), with French-
speaking students, who agreed that this was the best translation in this context.
For other languages, ‘hassled’ was translated variously as: a nuisance, cumber-
some, difficult, bothersome, troubling, tiresome, irksome, burdensome and com-
plicated. These were queried with translator and the developer to confirm concep-
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